Synergistic Anticancer Strategy of Sonodynamic Therapy Combined with PI-103 Against Hepatocellular Carcinoma

Drug Des Devel Ther. 2021 Feb 11:15:531-542. doi: 10.2147/DDDT.S296880. eCollection 2021.

Abstract

Purpose: Sonodynamic therapy (SDT) is considered a promising therapeutic strategy for the effective elimination of cancer cells. However, developing novel sonosensitizers with potentially high SDT efficacy remains a considerable challenge. Herein, we utilized near-infrared dye IR820 nanobubbles (NBs) combined with a dual PI3K/mTOR inhibitor PI-103 for the SDT treatment of hepatocellular carcinoma (HCC) in vitro.

Methods: The generated reactive oxygen species (ROS) were quantified using 2,7-dichlorodihydrofluorescein diacetate to determine the feasibility of using IR820 NBs as a potential sonosensitizer. The inhibition effects of the synergistic therapy was examined using the cell counting Kit 8 assay and apoptosis assay. JC-1 staining was performed to study mitochondrial membrane depolarization, and the transwell assay was used for cell migration analysis.

Results: The particle size and zeta potential of IR820 NBs were 545.5±93.1 nm and -5.19±1.73 mV, respectively. ROS accumulation was observed after HepG2 cells were treated with IR820 NBs under ultrasound irradiation. The SDT combined with PI-103 group inhibited cell viability and migration more strongly than the other groups (P < 0.01). The apoptosis assay also demonstrated a relatively high anti-HCC efficacy with the synergistic therapy, while JC-1 staining showed a decrease in the mitochondrial membrane potential after the combined treatment.

Conclusion: The combination of SDT and PI-103 was very effective in suppressing HCC proliferation, which might help develop new minimally invasive cancer treatment strategies.

Keywords: IR820 nanobubbles; PI3K/mTOR inhibitor; minimally invasive cancer treatment strategy; sonosensitizer.

MeSH terms

  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • Carcinoma, Hepatocellular / drug therapy*
  • Carcinoma, Hepatocellular / metabolism
  • Carcinoma, Hepatocellular / pathology
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • Combined Modality Therapy
  • Dose-Response Relationship, Drug
  • Drug Screening Assays, Antitumor
  • Furans / chemistry
  • Furans / pharmacology*
  • Hep G2 Cells
  • Humans
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / metabolism
  • Liver Neoplasms / pathology
  • Molecular Structure
  • Particle Size
  • Pyridines / chemistry
  • Pyridines / pharmacology*
  • Pyrimidines / chemistry
  • Pyrimidines / pharmacology*
  • Reactive Oxygen Species / metabolism
  • Structure-Activity Relationship
  • Ultrasonic Waves*

Substances

  • Antineoplastic Agents
  • Furans
  • PI103
  • Pyridines
  • Pyrimidines
  • Reactive Oxygen Species

Grants and funding

This research was supported by the National Natural Science Foundation of China (grant 81873900 to W.C.; grant 81801709 to H.J.).